Myeloablative Treatment Supported by Autologous Stem Cell Infusion with Neuroblastoma
Journal of Korean Medical Science
; : 184-190, 2003.
Article
em En
| WPRIM
| ID: wpr-126084
Biblioteca responsável:
WPRO
ABSTRACT
Bcr-abl antisense oligodeoxynucleotides (AS-ODNs) have provided evidence of an antileukemia effect when tested in vitro against Philadelphia-positive cells. In order to investigate the efficacy of AS-ODNs as purging agents in chronic myeloid leukemia (CML) patients, K562 cells, a human CML cell line, were treated in vitro with various types of AS-ODNs and interferon-alpha. Cells were treated in vitro for 0 and 36 hr with 40 microgram/mL of AS-ODNs, respectively, and incubated at 37 degrees C for 36 hr. Cytotoxic effects were measured by counting the number of viable cells as well as by MTT test. Clonogenic activities were evaluated by methylcellulose culture for 2 weeks. The effects of purging agents on the rearrangement of bcrabl gene were evaluated by RT-PCR. AS-ODNs inhibited the proliferation of K562 cells with time in cell count assay and MTT test. AS-ODNs were superior to INF-alpha in inhibiting clonogenic activity (recovery rate; 26.3% vs 64.0%). After incubation with bcr-abl AS-ODNs primers and mRNA isolated from K562 cells, positive bands were abolished, especially of b3a2 type and phosphorothioate type. Our results suggest that AS-ODNs mediated purging may be one of the efficient methods and that autograft may be an alternative treatment for allograft in high-risk group patients of CML if they do not have a stem cell donor.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Transplante Autólogo
/
Células-Tronco Hematopoéticas
/
Células Tumorais Cultivadas
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Oligonucleotídeos Antissenso
/
Proteínas de Fusão bcr-abl
/
Purging da Medula Óssea
/
Ensaio de Unidades Formadoras de Colônias
/
Neuroblastoma
Limite:
Humans
Idioma:
En
Revista:
Journal of Korean Medical Science
Ano de publicação:
2003
Tipo de documento:
Article